Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

7 Stocks to Buy With High ESG Momentum

If you’re looking for stocks to buy you might want to give companies with improving environmental, social and governance (ESG) ratings a try.

Why Tesla’s Shift to an Online Sales Model Is Positive for Tesla Stock

TSLA is closing its stores to save money; money that it can use to lower the actual price of its vehicles. The move will boost TSLA stock.

Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken

In 2018, Humalog generated $3.0 billion for Eli Lilly, 5% higher than a year earlier. Assuming Humalog’s gross margin is 73.8% (I’m using the company’s overall gross margin; it’s likely higher), Eli Lilly had $2.2 billion in gross profits from this single drug. Except for Trulicity, the company’s bestselling diabetes drug, Humalog is the company’s second-largest revenue and profit generator.

Should Big Tech Be Broken Up?

Senator Elizabeth Warren believes that the big tech stocks ought to be broken up. Whether it does indeed happen, it shouldn't be feared.

Boeing Stock: Should Investors Buy On Weakness In Wake Of Ethiopia Crash?

Don't mistake the terrible things that happen with a crappy company or stock. Boeing’s neither of those despite the current optics.